Legal Representation
Attorney
Paul C. Llewellyn
USPTO Deadlines
Next Deadline
650 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-05-04)
Due Date
May 04, 2027
Grace Period Ends
November 04, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
31 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 4, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 2, 2021 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Apr 1, 2021 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Mar 19, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Mar 19, 2021 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Mar 1, 2021 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Mar 1, 2021 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Oct 17, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 15, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 15, 2020 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Oct 15, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Apr 21, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 25, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 25, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 5, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 17, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jan 14, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 13, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 13, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 13, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 2, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 2, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 2, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 30, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 12, 2019 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Aug 12, 2019 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jul 20, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jul 19, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 18, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
| Jul 18, 2019 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Jul 18, 2019 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
First Use Anywhere:
Jul 12, 2012
First Use in Commerce:
Oct 15, 2014
Additional Information
Design Mark
The mark consists of an abstract representation of the DNA double helix structure.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005